Status:
COMPLETED
Tobramycin Administered by eFlow Rapid Nebulizer: Pharmacokinetic Study
Lead Sponsor:
Novartis
Conditions:
Cystic Fibrosis
Eligibility:
All Genders
6+ years
Phase:
PHASE1
Brief Summary
This study assesses the aerosol delivery characteristics (measured by nebulization time, serum and sputum tobramycin pharmacokinetic parameters) and safety of tobramycin administered for inhalation by...
Eligibility Criteria
Inclusion
- Male and female subjects aged 6 years or over at the time of screening,
- Chronically colonized with Pseudomonas aeruginosa.
- Diagnosis of cystic fibrosis (CF)
- Ability to expectorate sputum samples on command.
- Ability to tolerate a 1-week washout interval with no inhaled tobramycin or other aminoglycoside treatment.
- Clinically stable in the opinion of the investigator.
Exclusion
- Inhaled or intravenous aminoglycosides within 7 days before study drug administration.
- Any investigational drug within 2 weeks before screening.
- Loop diuretics within 7 days before study drug administration.
- Current use of inhaled tobramycin delivered by the PARI LC PLUS jet nebulizer without washout period of at least 1 week before entering the study.
- Women who are, or plan to become, pregnant during the course of the study.
- Serum creatinine or blood urea (BU) above the upper limit of normal for sex and age, or an abnormal urine analysis
- Known local or systemic hypersensitivity to aminoglycosides.
- Other protocol defined inclusion/exclusion criteria may apply.
Key Trial Info
Start Date :
April 1 2006
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00420836
Start Date
April 1 2006
Last Update
January 11 2007
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.